Scholarlink

Background <p>Nocardiosis, traditionally an opportunistic infection, lacks comprehensive characterization in immunocompetent individuals. This study aimed to describe and analyze the demographics, clinical features, and outcomes of <i>Nocardia</i> infections in this population based on the literature.</p> Methods <p>A systematic analysis of 530 immunocompetent <i>Nocardia</i> cases (2020–2024) was conducted using reports from PubMed, CNKI, and MedNexus. Demographics, exposures, clinical characteristics, laboratory, treatment, and outcome were recorded and analyzed.</p> Results <p>Patients (median age: 59 years; 69.8% male) exhibited pulmonary (46.5%), cutaneous (20.0%), or cerebral (15.7%) involvements. Risk factors included soil/dust exposure (97/530, 18.3%), trauma (44/530, 8.3%), and comorbidities (255/530, 48.1%, e.g., diabetes, bronchiectasis). Cure/improvement (82.6%) group exhibited younger age (<i>P</i> = 0.01) and higher prevalence of local infections (<i>P</i> &lt; 0.001), while more cases of disseminated infection (<i>P</i> &lt; 0.001), <i>N. farcinica</i> (<i>P</i> = 0.01), and unclassified <i>Nocardia</i> spp. (<i>P</i> = 0.02) were in the deterioration/mortality group. Trimethoprim-sulfamethoxazole (71.9%) was the primary therapy. Species-specific patterns demonstrated: <i>N. brasiliensis</i> preferentially linked to cutaneous infections (<i>P</i> &lt; 0.001), <i>N. farcinica</i> to cerebral disease (<i>P</i> &lt; 0.001), and <i>N. cyriacigeorgica</i> to pulmonary involvement (<i>P</i> &lt; 0.001).</p> Conclusion <p>Nocardiosis in immunocompetent hosts demonstrates distinct risk profiles, site-specific species associations, and prognostic factors. Early diagnosis, species identification, and antimicrobial therapy are critical for optimizing outcomes. This study underscores the need for heightened clinical suspicion and improved diagnostic protocols in non-immunocompromised populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical patterns, species-specific correlations, and therapeutic outcomes of nocardiosis in immunocompetent individuals: a systematic analysis based on literature

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月25日

查看全文
  • Le Lu,
  • Dongyi Wang,
  • Muzi Li,
  • Xiang Yang,
  • Kailun Zhou,
  • Zhiming Zhao,
  • Chunli Liu,
  • Wei Shang

摘要

Background

Nocardiosis, traditionally an opportunistic infection, lacks comprehensive characterization in immunocompetent individuals. This study aimed to describe and analyze the demographics, clinical features, and outcomes of Nocardia infections in this population based on the literature.

Methods

A systematic analysis of 530 immunocompetent Nocardia cases (2020–2024) was conducted using reports from PubMed, CNKI, and MedNexus. Demographics, exposures, clinical characteristics, laboratory, treatment, and outcome were recorded and analyzed.

Results

Patients (median age: 59 years; 69.8% male) exhibited pulmonary (46.5%), cutaneous (20.0%), or cerebral (15.7%) involvements. Risk factors included soil/dust exposure (97/530, 18.3%), trauma (44/530, 8.3%), and comorbidities (255/530, 48.1%, e.g., diabetes, bronchiectasis). Cure/improvement (82.6%) group exhibited younger age (P = 0.01) and higher prevalence of local infections (P < 0.001), while more cases of disseminated infection (P < 0.001), N. farcinica (P = 0.01), and unclassified Nocardia spp. (P = 0.02) were in the deterioration/mortality group. Trimethoprim-sulfamethoxazole (71.9%) was the primary therapy. Species-specific patterns demonstrated: N. brasiliensis preferentially linked to cutaneous infections (P < 0.001), N. farcinica to cerebral disease (P < 0.001), and N. cyriacigeorgica to pulmonary involvement (P < 0.001).

Conclusion

Nocardiosis in immunocompetent hosts demonstrates distinct risk profiles, site-specific species associations, and prognostic factors. Early diagnosis, species identification, and antimicrobial therapy are critical for optimizing outcomes. This study underscores the need for heightened clinical suspicion and improved diagnostic protocols in non-immunocompromised populations.